Drug
Tumor Infiltrating Lymphocytes LN 145
Tumor Infiltrating Lymphocytes LN 145: highest development phase Phase 2, developed by Iovance Biotherapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Iovance Biotherapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Tumor infiltrating lymphocytes (TIL) LN-145 NCT04111510 | Phase 2 | Metastatic Triple Negative Breast Cancer |
Latest
No recent events.
Follow Tumor Infiltrating Lymphocytes LN 145 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.